BIOMAT Database Logo BIOMAT Database Logo

A pilot study of low-dose zidovudine in human immunodeficiency virus infection. 1990

A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
Department of Medicine, University of Washington School of Medicine, Seattle.

BACKGROUND Zidovudine delays the progression of human immunodeficiency virus (HIV) infection but is associated with hematologic toxicity at high doses. Regimens are needed that preserve or enhance efficacy and reduce toxicity. Acyclovir has been reported to potentiate the effect of zidovudine on HIV in vitro. METHODS We conducted a Phase II open-label, dose-escalating trial to evaluate the clinical and antiviral effects of zidovudine at low (300 mg daily, 28 subjects), medium (600 mg, 24 subjects), and high (1500 mg, 15 subjects) doses, either with or without acyclovir (4.8 g) by random assignment. The subjects had the acquired immunodeficiency syndrome (AIDS)-related complex, but not AIDS. All of them had either HIV p24 antigenemia or plasma viremia and CD4-lymphocyte counts of 200 to 500 per cubic millimeter when they began treatment. RESULTS Performance scores and fatigue improved the most in the low- and medium-dose zidovudine groups (both P less than or equal to 0.025). Those assigned to low-dose zidovudine gained the most weight and had the greatest improvement in the mean CD4-lymphocyte count (from 321 per cubic millimeter at base line to 412 per cubic millimeter after 12 weeks, P = 0.01). The proportion of subjects in whom HIV antigenemia resolved, the decrease in the level of antigenemia, and the reduction in the plasma virus titers were similar at all three doses. Subjects assigned to receive the low or medium dose who subsequently crossed over to the 1500-mg dose (n = 19) did not have an increase in CD4-cell counts or a decline in levels of HIV antigen, but they did have dose-related toxicity. The addition of acyclovir to zidovudine was well tolerated, but it did not enhance any of zidovudine's antiretroviral effects. CONCLUSIONS In this pilot study a very low dose of zidovudine (300 mg) had clinical and virologic effects similar to those of higher daily doses (600 and 1500 mg). The minimal effective dose of zidovudine for the treatment of HIV infection has yet to be determined, and further studies of very low daily doses are warranted.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D010865 Pilot Projects Small-scale tests of methods and procedures to be used on a larger scale if the pilot study demonstrates that these methods and procedures can work. Pilot Studies,Pilot Study,Pilot Project,Project, Pilot,Projects, Pilot,Studies, Pilot,Study, Pilot
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U

Related Publications

A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
Cost effectiveness of low-dose zidovudine therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection.
May 1991, Annals of internal medicine,
A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
Phase I study of low-dose zidovudine and acyclovir in asymptomatic human immunodeficiency virus seropositive individuals.
December 1989, The American journal of medicine,
A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
Pharmacokinetic evaluations of low- and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection.
November 1991, Antimicrobial agents and chemotherapy,
A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
Low-dose zidovudine in children with an human immunodeficiency virus type 1 infection acquired in the perinatal period.
August 1991, Pediatrics,
A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection.
March 1990, Antimicrobial agents and chemotherapy,
A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study.
August 2004, European journal of clinical investigation,
A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
Zidovudine response relationships in early human immunodeficiency virus infection.
November 1993, Clinical pharmacology and therapeutics,
A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
A controlled trial of zidovudine in primary human immunodeficiency virus infection.
August 1995, The New England journal of medicine,
A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.
January 1994, The Journal of infectious diseases,
A C Collier, and S Bozzette, and R W Coombs, and D M Causey, and D A Schoenfeld, and S A Spector, and C B Pettinelli, and G Davies, and D D Richman, and J M Leedom
[Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection].
January 1993, Medicina clinica,
Copied contents to your clipboard!